5000亿！一战封神，他是中国最成功的美国人

Core Viewpoint - The article narrates the journey of BeiGene, a leading biopharmaceutical company in China, founded by John V. Oyler and Wang Xiaodong, highlighting its evolution from a startup to a global player in innovative drug development, overcoming significant challenges along the way [4][5]. Group 1: Investment and Founding - In 2010, John V. Oyler, an accomplished entrepreneur, and Wang Xiaodong, a prominent scientist, decided to establish a world-class biopharmaceutical company in China, aiming to innovate and sell drugs globally [4][6]. - Oyler's previous successes included selling BioDuro for $77 million and leading Genta to a valuation of $1.7 billion [6][7]. - The decision to base the company in China was driven by the country's large population, the return of trained scientists, and favorable government initiatives aimed at fostering innovation in drug development [10][11]. Group 2: Early Challenges - BeiGene faced severe financial constraints in its early years, with initial funding of just over $30 million, while drug development typically requires around $1 billion and ten years [13]. - The company attempted to license drugs from Johnson & Johnson but faced setbacks when the drugs did not perform as expected in clinical trials, leading to a significant morale drop within the team [14]. - Oyler sought funding from various sources, including investment firms and pharmaceutical companies, during a critical period when the company was on the brink of collapse [15]. Group 3: Strategic Decisions - In 2014, BeiGene opted for a "de-CRO" strategy, choosing to build its own clinical teams rather than outsourcing to contract research organizations, which was a common practice in the industry [18][19]. - The company expanded its internal clinical development team to over 3,000 members, allowing it to conduct trials in 45 countries and maintain control over costs and data quality [20]. - Oyler's leadership led to multiple successful public listings, including on NASDAQ and the Hong Kong Stock Exchange, which helped secure necessary funding [22]. Group 4: Major Partnerships and Growth - In 2017, BeiGene formed a strategic partnership with Celgene, which provided significant upfront payments and equity investment, enhancing its commercial capabilities [22][23]. - The company faced a crisis when Celgene was acquired by Bristol-Myers Squibb, leading to the termination of their partnership, but it quickly rebounded by securing a new partnership with Amgen [25][27]. - BeiGene's innovative drug, Brukinsa (Zebutinib), became a market leader after demonstrating superior efficacy in head-to-head trials against the established drug Imbruvica [31][33]. Group 5: Financial Performance and Future Outlook - By 2025, BeiGene reported sales of 27.595 billion yuan, a 44.21% increase year-on-year, and achieved a net profit of 1.139 billion yuan, marking a significant turnaround from previous losses [36]. - The company’s market capitalization exceeded 500 billion yuan, solidifying its position as a leading player in the Chinese pharmaceutical market [36]. - The planned rebranding to BeOne Medicines reflects its global ambitions and successful transition into a profitable biopharmaceutical enterprise [36].